An open-label multicentric clinical trial to evaluate the efficacy and impact on bone metabolism of recombinant human tumor necrosis factor-a receptor II IgG Fc fusion protein with methotrexate in active rheumatoid arthritis: 24-week clinical and radiographic results from Re ABLE study

National Medical Journal of China

Volumn 90, Issue 35, 2010, Pages 2481-2485

  Wu, Qing Jun ^a   Zhang, Zhuo Li ^b   Li, Zhen Bin ^b   Xu, Dong ^a   Li, Guang Tao ^b   Geng, Li Fen ^b   Li, Meng Tao ^a   Wang, Yu ^b   Zhu, Jian Jun ^b   Hao, Yan Jie ^b   Hui, Nai Ling ^b   Yang, Jing ^b   Cui, Xiao Qing ^b   Zhang, Xiao Gang ^b   Zhao, Yan ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b NONE

Author keywords

Rheumatoid arthritis; RhTNFR:Fc; Treatment

Indexed keywords

METHOTREXATE; RECOMBINANT LYMPHOTOXIN; ANTIRHEUMATIC AGENT; HYBRID PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR 2;

ARTICLE; BONE METABOLISM; CLINICAL ARTICLE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; FUNCTIONAL ASSESSMENT; HAND RADIOGRAPHY; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; OPEN STUDY; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WRIST RADIOGRAPHY; ADULT; CLINICAL TRIAL; DRUG COMBINATION; FEMALE; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

EID: 84871408418     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2010.35.010     Document Type: Article

References (21)

1. Drossaers-Bakker K W, de Buck M, van Zeben D, et al. Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum, 1999, 42: 1854-1860.
2. Eberhardt K B, Fex E. Functional impairment and disability in early rheumatoid arthritis: development over 5 years. J Rheumatol, 1995, 22: 1037-1042.
3. Pincus T, Sokka T, Wolfe F. Premature mortality in patients with rheumatoid arthritis: evolving concepts. Arthritis Rheum, 2001, 44: 1234-1236.
4. Choy E H, Panayi G S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med, 2001, 344: 907-916.
5. Moreland L W, Schiff M H, Baumgartner S W, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med, 1999, 130: 478-486.
6. Weinblatt M E, Kremer J M, Bankhurst A D, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor; Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med, 1999, 340: 253-259.
7. Bathon J M, Martin R W, Fleischmann R M, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med, 2000, 343: 1586-1593.
8. Genovese M C, Bathon J M, Martin R W, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum, 2002, 46: 1443-1450.
9. Genovese M C, Bathon J M, Fleischmann R M, et al. Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. J Rheumatol, 2005, 32: 1232-1242.
10. Klareskog L, van der Heijde D, de Jager J P, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis. Lancet, 2004, 363: 675-681.
11. Van der Heijde D, Klareskog L, Rodriguez-Valverde V, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum, 2006, 54: 1063-1074.
12. Van der Heijde D, Klareskog L, Landewe R, et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum, 2007, 56: 3928-3939.
13. Emery P, Breedveld F C, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etenercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomized, double-blind, parallel treatment trial. Lancet, 2008, 372: 375-382.
14. 2005, 9: 664-668.
15. 2007, 16: 1208-1211.
16. 2008, 2: 184-189.
17. Arnett F C, Edworthy S M, Bloch D A, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum, 1988, 31: 315-324.
18. Hochberg M C, Chang R W, Dwosh I, et al. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum, 1992, 35: 498-502.
19. Felson D T, Anderson J J, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum, 1995, 38: 727-735.
20. Van Gestel A M, Haagsma C J, van Riel P L. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum, 1998, 41: 1845-1850.
21. Van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol, 2000, 27: 261-263.